Bioanalytical Systems (BASI -6%) slides after reporting a big miss on it Q4 earnings earlier today. Quarterly revenue slid 19.7% Y/Y to $6.54 million, well under the $7.07 million the Street was expecting. The company blames the miss on about about $2.51M in restructuring charges, primarily consisting of U.K. exit costs, during the quarter. It notes however, that this is expected to be the final charge associated with the company's restructuring.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs